Company: PTHS
Filing Date: 2025-09-16
Form Type: 8-K/A
Source: 0001753926-25-001500
Chunk: 118

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-09-16
Form: 8-K/A
Chunk 118
---
111 |     |        | 149,608 |     |              | — |     |              | 20,000 |     |              | — |     |       | 210,115 |
| Chia-Lin Simmons |     |             | 14,396 |     |        |        |     |        | 183,675 |     |              | — |     |              | 20,000 |     |              | — |     |       | 218,071 |
| Peter Greenleaf  |     |             |      — |     |        |      — |     |        |       — |     |              | — |     |              |      — |     |              | — |     |       |       — |
| Matt Pauls       |     |             |      — |     |        |      — |     |        |       — |     |              | — |     |              |      — |     |              | — |     |       |       — |
| Rich Baxter      |     |             |      — |     |        |      — |     |        |       — |     |              | — |     |              |      — |     |              | — |     |       |       — |
| Scott Plesha     |     |             |      — |     |        |      — |     |        |       — |     |              | — |     |              |      — |     |              | — |     |       |       — |

(1) Amounts reflect the aggregate grant date fair value of the stock options granted to each named executive officer during the fiscal year ended December 31, 2024 and 2023, as computed in accordance with Financial Accounting Standards Board ASC 718.

Policies and Practices Related to The Grant of Certain Equity Awards

We maintain the Amended and Restated 2023 Plan through which we grant equity awards, including stock options and stock appreciation rights, to our named executive officers, other employees, and directors as part of our compensation program. In addition, certain employment agreements with our named executive officers provide for the grant of such equity awards. We do not currently have a formal policy governing the timing of grants of stock options, stock appreciation rights, or similar option-like instruments to named executive officers or directors in relation to the release of material nonpublic information. Equity awards under the Amended and Restated 2023 Plan have been granted from time to time, including to directors to